このページの翻訳は実験的なもので、現在開発中です。お待ちしております

H. Lundbeck マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Charl van Zyl

最高経営責任者

DKK 39.6m

報酬総額

CEO給与比率	6.8%
CEO在任期間	1.1yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

CEO報酬分析

H. Lundbeck の収益と比較して、Charl van Zyl の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

報酬と市場: Charlの総報酬 ($USD 5.85M ) は、 UK市場 ($USD 3.41M ) の同規模の企業の平均を上回っています。

報酬と収益: Charlの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Charl van Zyl (57 yo)

1.1yrs

在職期間

DKK 39,600,000

報酬

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Charl van Zyl	President & CEO	1.1yrs	DKK 39.60m	データなし
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.2yrs	DKK 10.90m	0.0023% DKK 946.2k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% DKK 15.9m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% DKK 5.8m
Tarek Samad	Senior VP & Head of Research	3.4yrs	データなし	データなし
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	データなし	データなし
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	データなし	データなし
Dianne Holto	Executive Vice President of People & Culture	less than a year	データなし	データなし
Ole Chrintz	Senior Vice President of International Markets	no data	データなし	データなし
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	データなし	データなし
Bjorn Mogensen	Senior Vice President of Group Finance	2.2yrs	データなし	データなし
Jose Molinuevo	VP & Head of Experimental Medicine	no data	データなし	データなし

2.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: HLUNBCの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% DKK 4.2m
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% DKK 2.6m
Jeffrey Berkowitz	Independent Director	6.6yrs	DKK 1.20m	データなし
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% DKK 3.2m
Jakob Riis	Director	1.6yrs	DKK 450.00k	0.0055% DKK 2.3m
Ilse Wenzel	Independent Director	3.6yrs	DKK 70.00k	データなし
Santiago Arroyo	Independent Director	3.6yrs	DKK 1.00m	データなし
Camilla Andersson	Employee Representative Director	2.6yrs	DKK 400.00k	0.00010% DKK 41.7k
Dorte Clausen	Employee Representative Director	2.6yrs	DKK 400.00k	0.00011% DKK 45.9k
Hossein Armandi	Employee Representative Director	2.6yrs	DKK 400.00k	データなし
Lasse Skibsbye	Employee Representative Director	2.6yrs	DKK 400.00k	データなし

3.6yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: HLUNBCの取締役会は経験豊富であると考えられます ( 3.3年の平均在任期間)。

H. Lundbeck マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Less than half of directors are independent

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

Recent updates

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24